Interchangeability and comparative effectiveness between generic and brand montelukast immediate release tablets after a single oral administration in healthy volunteers

Clinical and Translational Allergy

Rana Bustami¹  Nadia Ghazal³  Ayman Mousa²  Abdel Naser Zaid⁴ 

[1] Pharmaceutical Research Unit, Amman, Jordan;R&D Department Avalon Pharma (Middle East Pharmaceutical Industries Co. Ltd), Riyadh, Kingdom of Saudi Arabia;Naratech Pharma Consultancy, Amman, Jordan;Pharmaceutical Chemistry and Technology, Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine

关键词: Efficacy;    Safety;    Immediate release;    Bioequivalence;    Montelukast;   

Others  :  1232557
DOI  :  10.1186/s13601-015-0081-8

 received in 2015-07-23, accepted in 2015-10-16,  发布年份 2015

【 摘 要 】

Background

Montelukast is a leukotriene receptor antagonist. The release of leukotrienes causes narrowing and constricting in the respiratory airways. Blocking the action of these leukotrienes, montelukast can be used for the prophylaxis and treatment of chronic asthma.

Objective

The aim of this study was to evaluate the interchangeability and comparative effectiveness between a generic and a brand montelukast 10 mg immediate release tablets (Broncast ^®and Singulair ^® , respectively) after a single oral dose among Arab Mediterranean volunteers.

Methods

An open-label, randomized two-period crossover bioequivalence design was conducted in 31 healthy male volunteers with a 1 week washout between each study period and under fasting conditions. The plasma drug concentration was assessed by using a previously validated LC MS/MS method. The ratio between the generic and brand of geometric least squares means was reported for both generic and brand products. Moreover, an in vitro dissolution study was conducted on generic and brand tablets using three different pH media, and similarity and non-similarity factors (f2 and f1) were calculated.

Results

The used bioanalytical method was found to be linear within the range 6.098–365.855 ng/mL. The correlation coefficient was close to 0.999 during the course of the study validation. Statistical comparison of the main pharmacokinetic parameters showed the inexistence of any significant difference between generic and the brand. The point estimates (ratios of geometric means) were 111.939, 111.711, and 112.169 % for AUC _0–24 , AUC _0–∞ , and C _max , respectively. The 90 % confidence intervals (CIs) were within the pre-defined limits of 80.00–125.00 % as specified by the FDA and EMA for bioequivalence studies. F2 and f1 were higher than 50 and lower than 15, respectively in all selected pH media.

Conclusion

Broncast ^®immediate release film coated tablets (10 mg/tablet) are bioequivalent to Singulair ^®immediate release film coated tablets (10 mg/tablet), with a comparable safety and efficacy profile. This suggests that these two formulations can be clinically considered interchangeable. The dissolution study suggests that it could be used as premarketing quality control parameter in order to maintain the high quality of the produced product.

【 授权许可】

   
2015 Zaid et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]DrugBank: Montelukast sodium. Merck & Co. Inc. Whitehouse Station, NJ, 08889, USA. 2012.. http://pubchem.ncbi.nlm.nih.gov/compound/montelukast#section=Top webcite
• [2]LookChem®: Montelukast sodium. 2015.. http://www.lookchem.com/Product_30698/CasNo_151767-02-1/Montelukastsodium.html webcite
• [3]Merck: Singulair Montelukast sodium. Patient information Singulair®. Merck Sharp & Dohme Corp. 2012.. https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_ppi.pdf webcite
• [4]Merck: Singulair Montelukast sodium. The prescribing information for Singulair®. Merck Sharp & Dohme Corp. 2012.. https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf webcite
• [5]SINGULAIR. Comprimidos. MSD: http://www.medicamentosplm.com/productos/singulair_comprimidos_ masticables.htm.
• [6]Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, Schellenberg RR, McIvor RA: Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009, 16(Suppl A):17A-31A.
• [7]Blake KV: Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 1999, 33(12):1299-1314.
• [8]Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J: Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma 2012, 49(5):530-534.
• [9]Ducharme FM, Noya FJ, Allen-Ramey FC, Maiese EM, Gingras J, Blais L: Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 2012, 28(1):111-119.
• [10]Ghorwade V, Patil A, Patil S, Srikonda K, Kotagiri R, Patel P: Development and evaluation of fast-dissolving film of montelukast sodium. WJMPBS 2011, 1(1):06-12.
• [11]US Food and Drug Administration. FDA approves first generic versions of singulair to treat asthma, allergies. 2012.. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm314436.htm webcite
• [12]World Medical Association: “Declaration of Helsinike” as amended by the 59th world medical assembly. World Medical Association, Inc, Seoul; 2008.
• [13]EMA, European Medicines Agency: Note for guidance on good clinical practice. European Medicines Agency, London, UK; 1997. (CPMP/ICH/135/95)
• [14]ICH, International Conference on Harmonization. Harmonization tripartite guideline. Guidelines for good clinical practice. In: International conference of harmonization of technical requirements for registration of pharmaceuticals for human uses; 1996; Geneva, Switzerland.
• [15]US Food and Drug Administration. Guidance for industry: statistical approaches to establishing bioequivalence. 2001. http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1 webcite
• [16]Emami J: In vitro–in vivo correlation: from theory to applications. J Pharm Pharm Sci 2006, 9(2):169-189.
• [17]Fortunato D: Dissolution method development for immediate release solid oral dosage forms. Dissolution Technol 2005, 12(3):12-14.
• [18]European Medicines Agency. Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). London, UK; 2001.
• [19]Food and Drug Administration. Glossary of terms.. http://www.fda.gov/drugs/informationondrugs/ucm079436.htm webcite
• [20]Kanjanawart S, Gaysonsiri D, Tangsucharit P, Vannaprasaht S, Phunikhom K, Kaewkamson T, Wattanachai N, Tassaneeyakul W: Comparative bioavailability of two montelukast tablet formulations after single-dose administration in healthy Thai male volunteers. Int J Clin Pharmacol Ther 2011, 49:525-530.
• [21]Zheng R, Kim BH: Pharmacokinetics and bioequivalence of montelukast granules and montelukast tablets in Korean healthy volunteers. Int J Clin Pharmacol Ther 2014, 52:530-536.
• [22]Damle B, Duczynski G, Jeffers BW, Crownover P, Coupe A, LaBadie RR: Pharmacokinetics of a novel orodispersible tablet of montelukast in healthy subjects. Clin Ther 2014, 36:236-344.
• [23]Scaparrotta A, Di Pillo S, Attanasi M, Rapino D, Cingolani A, Consilvio NP, Verini M, Chiarelli F: Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med 2012, 7(1):13. BioMed Central Full Text
• [24]Muñoz E, Ocampo DO, Espinal EE, Yépes N: Bioequivalence study of two 10 mg montelukast immediate-release tablets formulations: a randomized, single-dose, open-label, two periods. Crossover Study. J Bioequiv Avail 2014, 6(3):086-090.
• [25]Sripalakit P, Maphanta S, Saraphanchotiwitthaya A: Bioequivalence study of two generic formulations of 10 mg montelukast tablets in healthy Thai male volunteers. Int J Clin Pharmacol Ther 2010, 48(9):628-632.
• [26]Public assessment report of the medicines: db.cbg-meb.nl/Pars/h111822.pdf. http://db.cbg-meb.nl/Pars/h111822.pdf. Accessed 18 Sept 2015.
• [27]Hayashi H: Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis. Yakugaku Zasshi 2013, 133(10):1079-1085.
• [28]Pedroso P, Almeida S, Filipe A, Neves RI, Boudreault S, Jiménez C: Bioequivalence studies for two different strengths of montelukast in healthy volunteers: 10 mg film-coated tablets and 5 mg chewable tablets. Drug Res (Stuttg) 2013, 63(9):477-483.
• [29]Blake KV: Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 1999, 33(12):1299-1314.
• [30]Cingi C, Gunhan K, Gage-White L, Unlu H: Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 2010, 120(9):1718-1723.
• [31]Modgill V, Badyal DK, Verghese A: Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol 2010, 32(9):669-674.
• [32]Yamamoto H, Yamada T, Sakashita M, Kubo S, Susuki D, Tokunaga T, Ogi K, Terasawa Y, Yamashita S, Kayano Y, Masada M, Kimura Y, Fujieda S: Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. Allergy Asthma Proc 2012, 33(2):e17-e22.
• [33]Fey C, Thyroff-Friesinger U, Jones S: Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin Transl Allergy 2014, 4:29. BioMed Central Full Text